

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1-11. (canceled).

12. (previously presented): A method for lowering postprandial blood glucose level and fasting blood glucose level without causing prolonged hypoglycemia, which comprises administering to a type II human diabetic patient within 10 minutes before starting meal 10 to 11 mg of a calcium salt of mitiglinide or mitiglinide calcium salt hydrate, as a single dose.

13. (cancelled).

14. (previously presented): A method as claimed in claim 12 wherein the single dose is 10 to 11 mg and the active ingredient is mitiglinide calcium salt hydrate.

15-23. (canceled).

24. (previously presented): A method as claimed in claim 12 wherein the type II diabetic patient is a human patient whose HbA<sub>1C</sub> value is not less than 6.5% and the 1 hour or 2 hour value of postprandial plasma glucose is not less than 200 mg/dL even after more than 8-week diet therapy.

25-33. (canceled).

34. (currently amended): A method as claimed in claim 12, which comprises administering to the type II human diabetic patient 10 to 11 mg of a calcium salt of mitiglinide or mitiglinide calcium salt hydrate three times a day within 5 minutes before starting each meal for 4 weeks or more.

35. (previously amended): A method as claimed in claim 14, which comprises administering three times a day within 5 minutes before starting each meal for 4 weeks or more.

36. (previously presented): A method as claimed in claim 24, which comprises administering three times a day within 5 minutes before starting each meal for 4 weeks or more.